INSIGHTS ON CELL & GENE MANUFACTURING AND LOGISTICS

• Quality Agreements, Tech Transfer & Risk Management In CGT

  Early quality, strong tech transfer, solid data discipline, and risk‑based decisions help accelerate advanced therapy programs and ensure compliance, scalability, and regulatory confidence.

• Quality Agreements, Tech Transfer, And Risk Management In CGT

  Advanced therapy success depends on early quality integration, effective tech transfer, data integrity, and aligned teams to ensure scalable, compliant manufacturing.

• Viral Safety Timeline

  Evolving science, contamination cases, and regulatory shifts shaped modern viral‑safety standards, prompting adoption of inactivation, filtration, molecular detection, and risk‑based methods.

• Mesenchymal Stromal Cells: The Progress And Manufacturing Challenges

  Understand the manufacturing challenges where rapid cell expansion often conflicts with therapeutic secretion profiles, requiring sophisticated quality control and donor selection strategies.

• USP <665> Becomes Official On May 1, 2026. Are You Ready?

  With USP <665> becoming official on May 1, 2026, proactive preparation is essential to ensure compliance and prevent delays, regulatory observations, or supply chain disruptions.

• Green Supply Chains Rarely Start With A Pledge; Target Waste Instead

  Effective sustainability strategies in pharma supply chains reduce rework and overage. Three leakage points offer the most practical starting point for rooting out waste.

• A Journey To Produce MSC-Derived Cell Therapies From Isolation To Large-Scale

  Drive successful MSC therapy development by optimizing isolation methods, surface chemistry, and closed-system expansion technologies to ensure cellular stability and commercial scalability.

• Scaling MSC Therapies: Overcoming Cell Therapy Manufacturing Risks And Barriers

  Achieve scalable MSC manufacturing by implementing closed systems and modular scale-out strategies that minimize contamination risks and ensure consistent cellular stability and efficacy.

• Bring The Power Of Electroporation To Accelerate Your Next Discovery

  Learn about a modular electroporation platform that processes 96 samples in three minutes with consistent transfection efficiency and viability across primary cells and cell lines.

• Why Choose A Modular Automated Approach To CAR T Manufacturing?

  Get a clear, data-driven look at the biggest pressure points in cell therapy manufacturing. Explore the trends shaping today’s production challenges and where new opportunities are emerging.